AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05343442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Description: Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable.
Study NCT05367492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Blind Varenicline
Description: For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, >55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks
Study NCT05367492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double Blind Placebo
Description: For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, >55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks
Study NCT05802056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study NCT05802056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05802056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT05802056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT or PET/MRI
Study NCT06246799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
Study NCT06246799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
Study NCT06246799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
Study NCT06246799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
Study NCT06246799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin: will be administered as a 100mg dose once daily.
Study NCT06246799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCI XR
Description: Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.
Study NCT05367492 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: QuitVaping
Description: QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
Study NCT05367492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QuitVaping
Description: QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
Study NCT05367492 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: This Is Quitting
Description: A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
Study NCT05367492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: This Is Quitting
Description: A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
Study NCT05644769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determine the presence of Human sequence Ang-(1-12) on no medication
Description: Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
Study NCT05644769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human sequence Ang-(1-12) on Lisinopril 40mg every day
Description: Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
Study NCT05554588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathrombus Thrombolysis During Primary PCI
Description: Intrathrombus Thrombolysis During Primary PCI
Study NCT05554588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration Thrombectomy During Primary PCI
Description: Aspiration Thrombectomy During Primary PCI
Study NCT05660538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Capsules for oral administration.
Study NCT05660538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.
Study NCT04815824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Mode
Description: Stationary cycling or treadmill walking
Study NCT05895929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: In vitro exposure of human nasal epithelial cells to mepolizumab
Study NCT05660538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to pregabalin)
Description: Placebo matched to pregabalin for oral administration.
Study NCT04684680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zamzam water
Description: will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
Study NCT04684680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tap water
Description: will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
Study NCT05722951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam &/or sodium valproate
Description: levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months
Study NCT05722951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam &/or sodium valproate
Description: levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months
Study NCT05722951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin + (levetiracetam \&/or sodium valproate) will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months
Study NCT04697069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Humanized monoclonal antibody
Study NCT04697069 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04778410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT04778410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
Study NCT04778410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
Study NCT04778410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
Study NCT04778410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
Study NCT04778410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
Study NCT04778410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Administered orally, 300 mg on Days 1-14 during each cycle
Study NCT06374056 — intervention group
Intervention type: DEVICE
Intervention: Kintsugi Voice Device
Description: The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression.~The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs.
Study NCT05629208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edecesertib
Description: Tablets administered orally
Study NCT05629208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Edecesertib Placebo
Description: Tablets administered orally
Study NCT06607003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax challenge agent derived from PvHMB-CCE001
Description: P. vivax challenge agent derived from PvHMB-CCE001 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
Study NCT06607003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax challenge agent derived from PvHMB-CCE002
Description: P. vivax challenge agent derived from PvHMB-CCE002 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
Study NCT04684342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Routine Laboratory investigations
Description: 1. Complete blood picture~2. Liver function test and prothrombine time \& concentration.~3. Blood urea and creatinine~4. Blood glucose, serum Na and K~5. CRP and ESR~6. Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers
Study NCT06664112 — intervention group
Intervention type: DEVICE
Intervention: AIDA Analysis
Description: The women will be followed until and after the birth, under intrapartum ultrasound monitoring, with all clinical, ultrasonographic and obstetric parameters, analyzed by AIDA method.
Study NCT05852366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste Preparation
Description: Dentifrice for management of dentinal hypersensitivity
Study NCT05852366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste Preparation
Description: Dentifrice for management of dentinal hypersensitivity
Study NCT05852366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste Preparation
Description: Dentifrice for management of dentinal hypersensitivity
Study NCT06376604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Subject will consume 6 cycles of 5-day fasting mimicking diet: 3 days prior to, the day of, and 1 day following chemotherapy treatments.
Study NCT06376604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 6 cycles of standard chemotherapy for the gynecologic malignancy.
Study NCT06376604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 6 cycles of standard chemotherapy for the gynecologic malignancy.
Study NCT05826665 — intervention group
Intervention type: OTHER
Intervention: Persistent AF ablation assisted with the STAR Apollo Mapping System
Description: This exploratory hypothesis generating data set will be collected during standard AF ablation procedures using FDA cleared technologies as described in their Instructions for Use (IFU). No randomization or experimental protocols will be used during this study, and all follow up will be performed as per the center's standard of care(SOC).
Study NCT05352477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy with thermal water
Description: Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
Study NCT05352477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balneotherapy with tap water
Description: Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
Study NCT05610449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testing Done Simple SARS CoV-2 Antigen Test
Description: Collections of specimens from subjects presenting with Covid-19 like symptoms or known/suspected exposure to SARS CoV-2 via nasal swabs administered by trained medical personnel.
Study NCT05376137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure (CPAP)
Description: CPAP comfort settings will be modified in the active group to be personalized to each participant
Study NCT05376137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure (CPAP)
Description: CPAP comfort settings will be modified in the active group to be personalized to each participant
Study NCT06034847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical thrombectomy in proximal large vessels
Description: mechanical thrombectomy with retrievable stents to remove clots in proximal large vessels, combined or not with distal aspiration, combined or not with IV thrombolytics
Study NCT06637969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based
Description: The experimental group was also provided with a total of 30 minutes of mindfulness training once a day for seven consecutive days. The content included mindful breathing awareness for 8 minutes while resting and lying in bed, 10 minutes of mindfulness meditation, 12 minutes of mindfulness body scanning, and 10 minutes of mindful walking and breathing. The control group The group received routine care, and a pre-test was conducted before the implementation of the interventional measures (from 7 pm to 9 pm the day before the operation), and a post-test was conducted after the seven-day intervention (from 7 pm to 9 pm on the seventh day of the interventional treatment). Comparison between the experimental group and the control group group differences
Study NCT06637150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpicilib
Description: Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.
Study NCT04871009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback Intervention
Description: InteraXon, Inc. produces the MUSE 2 wearable neurofeedback device and mobile application (heretofore referred to as the MUSE app), respectively comprising the electroencephalogram (EEG) hardware and interactive software components that will be used in this intervention. The MUSE 2 is an adjustable headband that is placed across the forehead and over and behind the ears. It contains EEG sensors for active sites across the forehead and behind the ears, and an additional reference site behind the ear. These sensors use EEG technology to passively record children's brainwaves. During a session, caregivers will help children place the MUSE 2 on their heads and connect it to the app on their personal device. Children's brain activity is recorded by the MUSE 2 and is represented on the app through audio-based feedback that children will listen to with earbuds, and use their volition to influence in real time, with the goal of gaining increased control over their own brain activity.
Study NCT04871009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard of care
Description: trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
Study NCT04871009 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
Study NCT06637150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endocrine therapy
Description: standard endocrine therapy
Study NCT06637150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine therapy
Description: standard endocrine therapy
Study NCT06644248 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colposcopy
Description: The intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection.
Study NCT06643923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: F (Frequency): 3 days per week, with a total of 24 sessions. I (Intensity): Low to moderate intensity exercises with progression, ensuring no fatigue is induced.~T (Time): Each session will last 30 minutes, over a total period of 8 weeks.~T (Type):~Warm-up exercises Core stabilization exercises: Aimed at improving core stability. Cool-down exercises E (Enjoyment): Gamified exercises, with sessions conducted to music. A (Adherence): A follow-up system will be implemented, including reminder notes and regular sending of session links to ensure compliance.
Study NCT06643923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.
Study NCT06643923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urotherapy
Description: The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.